Middle East Pharmaceutical Industries Co. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Middle East Pharmaceutical Industries Co.

Why is Middle East Pharmaceutical Industries Co. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

11.20%

EBIT Growth (5y)

8.29%

EBIT to Interest (avg)

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

50.10%

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

7.05

EV to EBIT

30.63

EV to EBITDA

26.04

EV to Capital Employed

6.53

EV to Sales

6.99

PEG Ratio

Dividend Yield

ROCE (Latest)

21.31%

ROE (Latest)

20.57%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -3.2% (YoY

-3What is not working for the Company

PRE-TAX PROFIT(Q)

At SAR 9.82 MM has Fallen at -60.69%

NET PROFIT(Q)

At SAR 8.28 MM has Fallen at -64.35%

Here's what is working for Middle East Pharmaceutical Industries Co.

Raw Material Cost

Fallen by -3.2% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation

Highest at SAR 5.21 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (SAR MM)

Here's what is not working for Middle East Pharmaceutical Industries Co.

Pre-Tax Profit

At SAR 9.82 MM has Fallen at -60.69%

over average net sales of the previous four periods of SAR 24.98 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (SAR MM)

Net Profit

At SAR 8.28 MM has Fallen at -64.35%

over average net sales of the previous four periods of SAR 23.22 MM

MOJO Watch

Near term Net Profit trend is negative

Net Profit (SAR MM)